Anebulo Pharmaceuticals (NASDAQ:ANEB) and Replimune Group (NASDAQ:REPL) Head-To-Head Comparison

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Valuation and Earnings

This table compares Anebulo Pharmaceuticals and Replimune Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-2.37
Replimune Group	N/A	N/A	-$247.30 million	($3.44)	-2.50

Replimune Group is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Anebulo Pharmaceuticals and Replimune Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Replimune Group	N/A	-102.69%	-72.22%

Volatility and Risk

Anebulo Pharmaceuticals has a beta of -0.7, suggesting that its share price is 170% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Anebulo Pharmaceuticals and Replimune Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1	1	0	0	1.50
Replimune Group	2	2	6	0	2.40

Anebulo Pharmaceuticals currently has a consensus price target of $3.00, indicating a potential upside of 566.37%. Replimune Group has a consensus price target of $10.00, indicating a potential upside of 16.14%. Given Anebulo Pharmaceuticals’ higher possible upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Replimune Group.

Summary

Anebulo Pharmaceuticals beats Replimune Group on 7 of the 11 factors compared between the two stocks.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

About Replimune Group

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.